VIVES is a multi-sector fund that invests in projects with a positive societal impact
The result of more than 15 years of research in the university laboratories of UCLouvain and multiple collaborations (ELEN department, ICTEAM), the VOCSens spin-off is developing a new concept of...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
SmartNodes is a provider of innovative control modules for dynamic outdoor lighting: "Light where and when you want, at the right level".
Maximum energy savings are achieved without reducing the...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Michel Detheux, CEO Iteos Therapeutics :
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease